Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women
Authors: Jean-Yves Reginster, René Rizzoli, John A. Kanis, Cyrus Cooper
Journal: Annals of Internal Medicine (2017)

Letters19 December 2017Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and WomenJean-Yves Reginster, MD, PhD, René Rizzoli, MD, PhD, John A. Kanis, MD, and Cyrus Cooper, MD, FMedSciJean-Yves Reginster, MD, PhDUniversity of Liège, Liège, Belgium (J.R.)Search for more papers by this author, René Rizzoli, MD, PhDGeneva University, Geneva, Switzerland (R.R.)Search for more papers by this author, John A. Kanis, MDCatholic University of Australia, Melbourne, Victoria, Australia (J.A.K.)Search for more papers by this author, and Cyrus Cooper, MD, FMedSciUniversity of Southampton, Southampton, United Kingdom (C.C.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0488 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Qaseem and colleagues (1) should be praised for recommending that clinicians offer pharmacologic treatment to reduce risk for spine and hip fracture in women with osteoporosis and consider treatment in women at high risk for fracture. However, the recommendations as currently formulated miss some important points. Vertebral and hip fractures undoubtedly present a major clinical, social, and economic burden (2). Nevertheless, several recent studies highlight the importance of nonhip and nonvertebral fractures. The considerable effect of these fractures on health care resources was well-established in GLOW (Global Longitudinal Study of Osteoporosis in Women), where they resulted in ...References1. Qaseem A, Forciea MA, McLean RM, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166:818-39. [PMID: 28492856]. doi:10.7326/M15-1361 LinkGoogle Scholar2. Kanis JA, Cooper C, Rizzoli R, Abrahamsen B, Al-Daghri NM, Brandi ML, et al; European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int. 2017;28:2023-34. [PMID: 28451733] doi:10.1007/s00198-017-4009-0 CrossrefMedlineGoogle Scholar3. Yang XC, Deng ZH, Wen T, Luo W, Xiao WF, Zhao RB, et al. Network meta-analysis of pharmacological agents for osteoporosis treatment and fracture prevention. Cell Physiol Biochem. 2016;40:781-95. [PMID: 27915335] CrossrefMedlineGoogle Scholar4. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al; ACTIVE Study Investigators. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316:722-33. [PMID: 27533157] doi:10.1001/jama.2016.11136 CrossrefMedlineGoogle Scholar5. Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: Results of the ACTIVExtend trial. Mayo Clin Proc. 2017;92:200-210. [PMID: 28160873] doi:10.1016/j.mayocp.2016.10.009 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Liège, Liège, Belgium (J.R.)Geneva University, Geneva, Switzerland (R.R.)Catholic University of Australia, Melbourne, Victoria, Australia (J.A.K.)University of Southampton, Southampton, United Kingdom (C.C.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0488. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoTreatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians Amir Qaseem , Mary Ann Forciea , Robert M. McLean , Thomas D. Denberg , and Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women Emily Frank Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women Mary Ann Forciea , Robert M. McLean , and Amir Qaseem Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women E. Michael Lewiecki Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women Susan Ott Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women Toshihiro Sugiyama Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women John J. Carey , E. Michael Lewiecki , Robert D. Blank , Chris R. Shuhart , and Bjoern Buehring Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women Paul D. Miller Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women Olivier Lamy , Bérengère Aubry-Rozier , and Elena Gonzalez-Rodriguez Metrics Cited byRecommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis FoundationReview of the guideline of the American College of Physicians on the treatment of osteoporosis 19 December 2017Volume 167, Issue 12Page: 902-903KeywordsDisclosureDrugsHip fracturesOsteoporosisParathyroid hormoneProspective studiesProteinsSafetySkeletonSpine ePublished: 19 December 2017 Issue Published: 19 December 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...